Ligand to Earn 9% Royalties as FDA Approves Travere’s FILSPARI for Rare Kidney Disease
Event summary
- FDA granted full approval to Travere Therapeutics' FILSPARI for treating focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.
- Ligand Pharmaceuticals is entitled to a 9% royalty on worldwide net sales of FILSPARI.
- FILSPARI is the first and only FDA-approved medicine for FSGS, expanding beyond its existing approval for IgA nephropathy (IgAN).
- The DUPLEX Phase 3 study showed FILSPARI reduced proteinuria by 48% in FSGS patients without nephrotic syndrome compared to 27% for irbesartan.
- Travere estimates the addressable U.S. population for FSGS without nephrotic syndrome exceeds 30,000 individuals.
The big picture
Ligand’s royalty model benefits from Travere’s success in securing FDA approval for FILSPARI in FSGS, a rare and serious kidney disorder. This approval diversifies FILSPARI’s market potential beyond IgAN, positioning it as a key driver of Ligand’s royalty income. The strategic significance lies in Ligand’s ability to monetize its partnerships through high-value, long-term economic interests in approved therapies, aligning its financial performance with clinical and commercial success.
What we're watching
- Royalty Growth
- How the expansion of FILSPARI into FSGS will impact Ligand’s long-term royalty revenue streams.
- Market Penetration
- Whether Travere can effectively target the estimated 30,000+ FSGS patients in the U.S. without nephrotic syndrome.
- Competitive Dynamics
- The pace at which other therapies may emerge to challenge FILSPARI’s position in the rare kidney disease market.